Latus
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2929 Arch St Fl 8 Ste 2, Philadelphia, P...Phone Number
(215) 995-0890Website
www.latusbio.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Latus
Latus is a biotechnology company dedicated to addressing devastating CNS and peripheral diseases via innovative and scalable gene therapies. The Company is advancing a broad therapeutics pipeline based on novel AAV capsid variants with potency and specificity. Latus is powered by a diverse team of visionary scientists, experienced clinicians, and leading industry executives.Explore more
Latus Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Latus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Latus has recently received funding, and reach out quickly before it becomes old news!
Click to see if Latus had a recent Job posting/layoffs
Earning: See what the market has to say on Latus recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Latus is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Latus has new funding data
Congratulate Masked Content for being promoted to Masked Content at Latus
Product Launch: Get notified when Latus launches new products
Latus, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Latus
Find 3 more new buyers
Company Profile Activity
Activity Insights
Latus is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Latus is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Latus.
Latus financials insights
Gather financial insights about Latus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series A
$97M
Most Recent Scoops
Funding
Funding
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Person-Based
Latus News & Media
Latus Bio Strengthens Executive Team with Appointments of Ainslie Little as COO and Katie Hewitt as interim CBO
BOSTON--(BUSINESS WIRE)-- #Impact--Latus Bio, Inc. (Latus), a biotechnology company driving advances in AAV gene therapy, announces the appointments of Ainslie Little, PhD, as COO and Katie Hewitt, as interim CBO. “These appointments reflect our continued commitment to building a world-class organization. Ainslie’s operational leadership and Katie’s business development expertise will be instrumental as we progress our programs and expand the scope of our partnerships.” - P. Peter Ghoroghchian,Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain
PHILADELPHIA--(BUSINESS WIRE)-- #BattensDisease--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, “AAVs engineered for robust brain transduction drive therapeutically relevant expression of secreted recombinant protein in NHPs and a mouse model of lysosomal storage disease.” The study, led by Latus founder Beverly Davidson, PhD details the development of a novel adeno-associatedLatus Bio Announces Multiple Oral and Poster Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting
PHILADELPHIA--(BUSINESS WIRE)-- #AAV--Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting, which is being held from May 13-17th, 2025 in New Orleans, LA. These presentations showcase progress toward advancing Latus’ novel AAV capsid variants - AAV-DB-3 and AAV-Ep+ - to address Huntington’s Disease and CLN2 Batten Disease, respectively.Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
PHILADELPHIA--(BUSINESS WIRE)-- #AAV--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug candidate at the 20th Annual CHDI Huntington’s Disease (HD) Therapeutics Conference in Palm Springs, California, which is being held from February 24-27, 2025. Latus will share progress toward the development of a novel, investigational, AAV drug candidate that is intended to address somatic in
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Latus
Sign Up For FreeTo access detailed company insights
Latus is a biotechnology company dedicated to addressing devastating CNS and peripheral diseases via innovative and scalable gene therapies. The Company is advancing a broad therapeutics pipeline based on novel AAV capsid variants with potency and specificity. Latus is powered by a diverse team of visionary scientists, experienced clinicians, and l... Read More
